Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Biotech & Genomic Medicine▲

Seaport Therapeutics IPO Draws Big Pharma Attention

Seaport Therapeutics has emerged as a potential acquisition target for major pharmaceutical companies following its May 2026 IPO. The company's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for major depressive disorder and topline results expected in the first half of 2027. Bristol Myers Squibb, which previously paid $14 billion for Karuna Therapeutics co-founded by Seaport CEO Daphne Zohar, is ranked as the top potential acquirer. Johnson & Johnson, AbbVie, and Sanofi are also named as plausible buyers. Seaport completed an upsized $260 million IPO and holds $427.26 million in cash, guiding to a runway into 2029.

SPTX ▲BMY

Biotech & Genomic Medicine

24/7 Wall St.·6dRead more ▾